Mirum Pharmaceuticals, Inc. (MIRM) Return on equity 2020–2025
Mirum Pharmaceuticals, Inc. (MIRM) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-7.4%FY2025 · since FY2020: -60.0% → -7.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -7.4% | +31.6 pp |
| FY2024 | -39.0% | +26.7 pp |
| FY2023 | -65.7% | +29.8 pp |
| FY2022 | -95.5% | -25.6 pp |
| FY2021 | -69.9% | -9.9 pp |
| FY2020 | -60.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice